Tonix Pharmaceuticals Holding Corp.
Close on Oct 19, 2026
- Market cap
- $95.32M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 26, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | Before market open | $13.54M | $-2.44 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 1, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 13, 2026 | Before market open | $5.40M | $-3.98 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 27, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 25, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 25, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 3, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 28, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 9, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 1, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | After market close | – | – | – |
Press releases
Announcements Tonix Pharmaceuticals filed with the SEC
Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA ®
Other events · EX-99.01 to Form 8-K
Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer
Other events · EX-99.01 to Form 8-K
Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
Results of operations · EX-99.01 to Form 8-K
Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
Tonix Pharmaceuticals Announces Major Managed Medicare
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
EX-99.02 to Form 8-K
Regulation FD disclosure · Other events · EX-99.02 to Form 8-K
TNX-4800: A LONG-ACTING, BACTERICIDAL, HUMAN MONOCLONAL ANTIBODY TO PREVENT LYME DISEASE IN THE U.S.
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
PRESS RELEASE OF THE COMPANY, DATED MAY 11, 2026
Results of operations · EX-99 to Form 8-K
TONIX PHARMACEUTICALS HOLDING CORP. FORM 8-K
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
TONIX PHARMACEUTICALS HOLDING CORP. 8-K
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
TNX-4800: A MONOCLONAL ANTIBODY (MAB) TO PROTECT AGAINST LYME DISEASE
Regulation FD disclosure · Other events · EX-99.02 to Form 8-K
PRESS RELEASE OF THE COMPANY, DATED APRIL 22, 2026
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
IN VITRO CHARACTERIZATION OF FULLY HUMAN ANTAGONISTIC ANTI-BTLA MONOCLONAL ANTIBODIES
Regulation FD disclosure · Other events · EX-99.02 to Form 8-K
PHARMACOKINETICS OF TNX-1700 IN NON-HUMAN PRIMATES AND HUMAN FCRN/SERUM ALBUMIN TRANSGENIC MICE
Regulation FD disclosure · Other events · EX-99.03 to Form 8-K
TONIX PHARMACEUTICALS HOLDING CORP 8-K
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
CORPORATE PRESENTATION, MARCH 31, 2026
Regulation FD disclosure · Other events · EX-99.02 to Form 8-K
TONIX PHARMACEUTICALS HOLDING CORP. 8-K
Regulation FD disclosure · Other events · EX-99.03 to Form 8-K
TONIX PHARMACEUTICALS HOLDING CORP 8-K
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
Tonix Pharmaceuticals Reports Fourth Quarter and
Results of operations · EX-99.01 to Form 8-K
PRESS RELEASE OF THE COMPANY, MARCH 10, 2026
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
Tonix Pharmaceuticals Holding Corp. 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
TONIX PHARMACEUTICALS HOLDING CORP. 8-K
Material agreement · Other events · EX-99.01 to Form 8-K
Tonix Pharmaceuticals Holding Corp. 8-K
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
PRESS RELEASE OF THE COMPANY, DECEMBER 9, 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
TONIX PHARMACEUTICALS HOLDING CORP. 8-K
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
PRESS RELEASE OF THE COMPANY, DATED NOVEMBER 4, 2025
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
TONIX PHARMACEUTICALS HOLDING CORP 8-K
Results of operations · EX-99.01 to Form 8-K
Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE OF THE COMPANY SEPTEMBER 17, 2025
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
PRESS RELEASE OF THE COMPANY, SEPTEMBER 30, 2025
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
PRESS RELEASE OF THE COMPANY, SEPTEMBER 29, 2025
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
TONIX PHARMACEUTICALS HOLDING CORP. 8-K
Regulation FD disclosure · Other events · EX-99.02 to Form 8-K
Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
PRESS RELEASE OF THE COMPANY SEPTEMBER 17, 2025
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
US APPROVAL OF TONMYA(TM) FOR THE TREATMENT OF FIBROMYALGIA
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K
TONIX PHARMACEUTICALS HOLDING CORP 8-K
Regulation FD disclosure · Other events · EX-99.01 to Form 8-K